Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series.
Fluge, Øystein, Mella, Olav · BMC neurology · 2009 · DOI
Quick Summary
This study examined whether a drug called rituximab, which reduces B cells (a type of immune cell), could help ME/CFS patients. Three ME/CFS patients received rituximab infusions and all experienced significant symptom improvement lasting several months. When symptoms returned, patients were retreated and improved again, suggesting that B cells may play a role in ME/CFS for at least some patients.
Why It Matters
This study was the first to systematically test whether reducing B cells could improve ME/CFS symptoms, providing preliminary evidence that immune dysfunction—specifically B-cell dysfunction—may contribute to ME/CFS in some patients. This finding opened new avenues for understanding the biological basis of ME/CFS and for developing targeted immunotherapies, shifting the field toward investigating specific immune mechanisms rather than treating ME/CFS as purely psychiatric.
Observed Findings
All three patients showed improvement of all ME/CFS symptoms following rituximab infusion, with onset 6 weeks post-treatment.
Symptom relief lasted 16, 18, and 44 weeks respectively in the three patients before relapse occurred.
Upon retreatment with rituximab, all three patients again showed marked symptom improvement matching their first response.
One patient (Patient 1) also showed symptom improvement following oral methotrexate, another B-cell depleting agent.
No unexpected toxicity was reported from rituximab treatment.
Inferred Conclusions
B lymphocytes are involved in ME/CFS pathogenesis for at least a subset of patients.
B-cell depletion represents a potentially therapeutic strategy for ME/CFS, warranting more systematic investigation.
The pattern of symptom improvement, delayed onset, and reproducible relapse kinetics suggest B cells play a significant role in ongoing ME/CFS clinical features.
ME/CFS may be amenable to targeted immunomodulatory therapies that modify B-cell number and function.
Remaining Questions
Which ME/CFS patients are most likely to respond to B-cell depletion therapy, and what biological markers might predict responders?
What This Study Does Not Prove
This case series does not prove that B-cell depletion cures ME/CFS or that it works for all patients—only three patients were treated, and symptoms eventually returned in all cases. It does not establish causation (that B cells cause ME/CFS) or identify which ME/CFS patients would benefit; broader controlled trials are needed to determine efficacy, optimal dosing, patient selection, and long-term safety. The delayed response (weeks 6–26) and variable relapse timelines also suggest the mechanism is complex and not yet understood.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →